Dainippon Sumitomo Pharma Co., Ltd.License Agreement • May 10th, 2018 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations
AMENDMENT NO. 3 to LICENSE AGREEMENTLicense Agreement • May 10th, 2018 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 3 (“Amendment”) to that certain License Agreement dated March 29, 2011 (as amended by the amendment No.1 as of June 8, 2011 and the amendment No.2 as of September 16, 2011, collectively, the “Agreement”) is made and entered into as of February 13, 2018, by and between Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”), a company organized under the law of Japan, having a place of business at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045 Japan, and Intercept Pharmaceuticals, Inc. (“Intercept”), a company organized under the law of the State of Delaware, having a place of business at 10 Hudson Yards, 37th floors, New York, NY 10001 U.S.A.
Dainippon Sumitomo Pharma Co., Ltd. 6-8, Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan Phone : (81) 6 (6203) 4531 Telefax : (81) 6 (6203) 4533License Agreement • May 10th, 2018 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations
